AstraZeneca

AstraZeneca reported third-quarter revenue up 7% to about $16.2 billion and a group net profit of roughly $3.1 billion (around +25%). Adjusted earnings per share beat analysts’ expectations; the cancer drugs division grew 17% to just under $7.8 billion and accounted for almost half of sales, while revenue in the cardiovascular, renal and metabolism area fell by about one fifth to $2.6 billion. CEO Pascal Soriot confirmed the targets for 2026 and 2030; for the current year, currency‑adjusted sales growth in the mid‑to‑high single digits and a low‑double‑digit increase in adjusted earnings per share are expected. The shares jumped sharply after the results. » More on finanzen.net

Astrazeneca reports a 7% rise in third-quarter revenue to about $16.2 billion and a 25% increase in net income to $3.1 billion, both above market expectations. Revenue was driven by cancer drugs, whose sales rose 17% to nearly $7.8 billion, making up almost half of group sales, while cardiovascular, renal and metabolic medicines fell by around one fifth. CEO Pascal Soriot reaffirms targets for 2026 and 2030; analysts at Bernstein, Jefferies and UBS confirm or raise buy ratings and lift price targets. The stock jumped sharply, topping the 200-day moving average; the dividend yield is around 2.0%. » More on deraktionaer.de

AstraZeneca reported a 7% rise in third-quarter revenue to about $16.2 billion and a roughly 25% increase in net profit to $3.1 billion. Sales of cancer drugs rose 17% to just under $7.8 billion, while revenues in the cardiovascular, renal and metabolic segment fell by about one-fifth to $2.6 billion. CEO Pascal Soriot said the company is on track to meet its 2026 and 2030 targets; for 2024 AstraZeneca expects currency-adjusted mid- to high-single-digit revenue growth and low-double-digit growth in adjusted earnings per share. In London the stock rose as much as about 2.9% and traded at £134.36. » More on finanzen.net

The EU Commission has approved Enhertu from AstraZeneca and Daiichi Sankyo as monotherapy for patients with residual disease after surgically removed HER2‑positive early-stage breast cancer. The approval, the first for Enhertu with curative intent in the early-stage setting, is based on Phase III data that reduced the risk of recurrence or death. The AstraZeneca stock showed only a slight reaction to the news. » More on finanzen.net

Astrazeneca has agreed with Oracle on a collaboration that links Astrazeneca's scientific expertise with Oracle's real-world data, cloud and AI capabilities. The aim is to evaluate selected use cases, make clinical trials more efficient, generate evidence across the entire drug lifecycle and improve patient care. The cooperation is non-binding and is intended to help identify patients earlier and increase trial success rates. » More on deraktionaer.de